RESEARCH TRIANGLE PARK – Shares in Biogen, the drug giant that has a major presence in RTP, surged Wednesday when rumors emerged that the company was exploring a possible acquisition by Samsung Biologics.

However, the report was deined by the South Korea-based company. Shares were off some 5% in pre-market trading Thursday after that denial.

Biogen (Nasdaq: BIIB) has declined comment.

Reuters reported details of a potential deal on Wednesday and updated its reporting overnight.

“Stock up about 10% on the news, and the sale price approximately $40 billion,” Yahoo Finance reported.

Are layoffs about to hit Biogen workforce? Drug giant won’t comment

Ground breaking: Biogen’s $200M RTP gene therapy facility means new jobs